Successful results of 5-year test data opens potential opportunity for long-term recording applications for Parkinson’s disease, epilepsy, spinal cord stimulation, neurological disorders, and research markets.
EDEN PRAIRIE, Minn., Feb. 8, 2022 /PRNewswire/ — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it successfully completed initial pre-clinical long-term testing of recording capabilities on its platform thin film electrode technology. In test procedures, the electrodes’ ability to record electrical activity over a span of 5 years was measured using an accelerated aging test model. The test results demonstrated NeuroOne’s thin film electrodes’ reliability against environmental factors that may contribute to device failure or malfunction, which is a well-established challenge with thin film electrode technology.
Dave Rosa, CEO of NeuroOne commented, “We are excited with the results of our initial long-term testing of recording capabilities for our thin film electrode technology. These results support the potential expansion of utilization of these electrodes for long-term recording for indications such as epilepsy, Parkinson’s disease, chronic back pain due to failed back surgeries, other related neurological disorders as well as research applications. We also believe that in the near term it may provide an opportunity to enter the research market as well as offering the potential for strategic licensing agreements in certain markets.”
The tests performed by the Company are accelerated soak tests. These tests are widely used in the field of neurotechnology allowing for comparison between NeuroOne’s electrodes and other approaches in academic and industry settings. Camilo Diaz-Botia, Director of Electrode Development for NeuroOne, said, “There are many known failure modes of chronically implantable electrodes. For thin film devices in particular, reliable insulation is an important challenge because reduction of the amount of material puts electrical signals of interest closer to detrimental factors like moisture, corrosion, and noise, which may contribute to device malfunction or failure. For all the tests performed at different acceleration factors, our devices demonstrated reliable insulation, as determined by electrochemical characterization methods, beyond 5 years of real time use, solving one of the most significant failure modes of thin film electrodes.”
The Company also expects to release long-term data in the near future on electrodes that would provide therapeutic stimulation for the same applications mentioned earlier.
As previously reported, NeuroOne is also advancing a pipeline of therapeutic electrode technologies for brain tissue ablation, chronic stimulation use for DBS (deep brain stimulation) and spinal cord stimulation for chronic back pain. The Company believes these therapeutic electrode technologies are targeted to addressable markets of over $10 billion.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com .
